key: cord-0733642-5l9lpcj6
authors: Klimek, Ludger; Akdis, Cezmi A.; Jutel, Marek; Zuberbier, Torsten; Bousquet, Jean
title: Inhaled Corticosteroids in early COVID‐19—A tale of many facets
date: 2021-08-27
journal: Allergy
DOI: 10.1111/all.15041
sha: 5a3fdc7ed15bded5abd5ac9f1d965d6698ddfd9d
doc_id: 733642
cord_uid: 5l9lpcj6

nan

To the Editor Following our early report in Allergy, 1 F I G U R E 1 SARS-CoV-2 is entering the airways epithelial cells via ACE2-receptors. The study aims to proof protection in respond to SARS-CoV-2 infection using topical Budesonide. In general, this study does not allow to generate sufficient information to answer the question, whether early treatment with Budesonide is protecting against severe courses of COVID-19 

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

ARIA-EAACI statement on asthma and COVID-19

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper

Asthma-associated risk for COVID-19 development

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

The placebo effect in asthma

Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial